NTLA Intellia Therapeutics, Inc. Stock Quote

NTLA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	1.20%	Shs Outstand	67.18M	Perf Week	4.85%
Market Cap	9.66B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-67.87%	Shs Float	64.74M	Perf Month	-15.22%
Income	-148.60M	PEG	-	EPS next Q	-0.63	Inst Own	83.00%	Short Float	5.25%	Perf Quarter	92.76%
Sales	51.50M	P/S	187.51	EPS this Y	-13.80%	Inst Trans	-0.35%	Short Ratio	1.52	Perf Half Y	96.81%
Book/sh	8.13	P/B	17.07	EPS next Y	-7.50%	ROA	-25.40%	Target Price	138.44	Perf Year	620.99%
Cash/sh	8.39	P/C	16.54	EPS next 5Y	30.00%	ROE	-33.90%	52W Range	16.54 - 202.73	Perf YTD	155.13%
Dividend	-	P/FCF	-	EPS past 5Y	-46.70%	ROI	-	52W High	-32.82%	Beta	2.12
Dividend %	-	Quick Ratio	9.90	Sales past 5Y	57.20%	Gross Margin	-	52W Low	723.46%	ATR	12.23
Employees	312	Current Ratio	9.90	Sales Q/Q	-50.40%	Oper. Margin	-	RSI (14)	52.66	Volatility	6.16% 7.16%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-9.20%	Profit Margin	-	Rel Volume	0.56	Prev Close	138.79
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 05 BMO	Payout	-	Avg Volume	2.24M	Price	136.20
Recom	2.10	SMA20	-3.98%	SMA50	20.64%	SMA200	89.24%	Volume	557,133	Change	-1.87%

Jun-28-21

Reiterated

H.C. Wainwright

Buy

$111 → $171

Jun-11-21

Initiated

H.C. Wainwright

Buy

$111

May-07-21

Upgrade

ROTH Capital

Neutral → Buy

$75 → $80

May-04-21

Initiated

RBC Capital Mkts

Outperform

$110

Mar-04-21

Initiated

JMP Securities

Mkt Outperform

$80

Dec-22-20

Downgrade

Robert W. Baird

Outperform → Neutral

$60

Oct-27-20

Initiated

Truist

Buy

$40

Oct-14-20

Initiated

Wells Fargo

Overweight

Sep-18-20

Initiated

Goldman

Buy

$33

Feb-28-20

Upgrade

Oppenheimer

Perform → Outperform

Feb-14-20

Downgrade

Wedbush

Outperform → Neutral

$16

Nov-01-19

Upgrade

Raymond James

Mkt Perform → Outperform

Jul-09-19

Initiated

Robert W. Baird

Outperform

$23

Jun-10-19

Initiated

ROTH Capital

Neutral

$16

May-03-19

Upgrade

Wedbush

Neutral → Outperform

$20 → $21

Apr-12-19

Initiated

Evercore ISI

Outperform

Nov-02-18

Downgrade

Wedbush

Outperform → Neutral

$36 → $20

Oct-29-18

Initiated

Credit Suisse

Neutral

$24

Sep-21-18

Initiated

Raymond James

Mkt Perform

May-15-18

Upgrade

Chardan Capital Markets

Neutral → Buy

$20 → $57.50

Aug-02-21 08:52AM	Intellia (NTLA) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-29-21 03:05PM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates GlobeNewswire
Jul-27-21 05:50PM	Intellia Therapeutics, Inc. (NTLA) Dips More Than Broader Markets: What You Should Know Zacks
Jul-16-21 11:02AM	Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week Motley Fool
05:32AM	What Type Of Shareholders Make Up Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Share Registry? Simply Wall St.
Jul-15-21 08:19AM	After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding Motley Fool
Jul-12-21 03:12PM	WHO Issues Framework For Governance For Gene Editing Technologies Benzinga
Jul-11-21 07:01AM	Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results Motley Fool
Jul-10-21 05:19AM	Is It Too Late to Buy Intellia Therapeutics? Motley Fool
Jul-09-21 04:04PM	A Comprehensive Guide to Genomic ETFs Zacks
Jul-06-21 11:28AM	Hedge Funds Are Cashing Out Of Intellia Therapeutics, Inc. (NTLA) Insider Monkey -8.71%
Jul-04-21 07:49AM	2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't Motley Fool
Jul-02-21 04:35PM	Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus Investor's Business Daily
04:01PM	Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock GlobeNewswire
12:48PM	Here's What Drove Gene Editing Stocks Higher This Week Motley Fool
Jul-01-21 06:56AM	5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now Motley Fool +6.02%
Jun-30-21 10:14PM	German Launch Startup Pitches Taxi to Space: Catalyst Update Bloomberg +6.79%
04:20PM	Why Intellia Therapeutics Was a Winner on Wednesday Motley Fool
04:04PM	Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More Zacks
03:30PM	In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC Benzinga
01:14PM	Genomics ETFs Surge on a Major Breakthrough in CRISPR Study Zacks
12:14PM	Intellia Therapeutics Leads Gene-Editing Stock Rally TheStreet.com
11:32AM	Here Are the Best and Worst Biopharma Stock Performers So Far This Year Barrons.com
08:46AM	Implied Volatility Surging for Intellia Therapeutics (NTLA) Stock Options Zacks
06:47AM	Can Intellia Therapeutics Turn Exciting Trial Results into Profits? Motley Fool
06:42AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals Zacks
Jun-29-21 09:08PM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +13.63%
11:20AM	Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data Zacks
09:55AM	3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data Zacks
09:34AM	Company News for Jun 29, 2021 Zacks
06:58AM	Intellia Seeks To Raise $400M Via Equity Benzinga
05:15AM	Intellia Therapeutics Busts Out of Resistance on Positive Trial News TheStreet.com
Jun-28-21 04:25PM	Cathie Wood Funds Jump as Gene Editing Edges Closer to Reality Bloomberg +50.21%
04:12PM	Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR Investor's Business Daily
04:01PM	Intellia Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
02:36PM	Nasdaq surges to record, FAA stalls Boeing 777X, airline stocks nosedive, AMC & GameStop jump Yahoo Finance Video
01:17PM	Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money Motley Fool
12:22PM	Why Beam Therapeutics Jumped Today Motley Fool
12:17PM	Why Editas Medicine Stock Is Jumping Today Motley Fool
11:09AM	Why Intellia Therapeutics Stock Is Skyrocketing Today Motley Fool
10:39AM	Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough Barrons.com
10:02AM	Dow Jones Lags, Nasdaq Leads In Mixed Open; Biotechs Rocket On Intellia CRISPR News; Salesforce.com Stock Climbs Investor's Business Daily
10:00AM	Baird suspends GameStop, Virgin Galactic and Intellia Therapeutics soar Yahoo Finance Video
09:15AM	Trading Intellia Therapeutics, ARKG ETF After Breakthrough Data TheStreet.com
08:41AM	5 Top Stock Gainers for Monday: Intellia Therapeutics, QAD, Etsy, Nvidia TheStreet.com
08:39AM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
06:09AM	Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate Benzinga
05:34AM	Intellia Soars On Positive Results In Gene-Editing Treatment Investing.com
04:52AM	Premarket Movers Monday: Intellia Therapeutics, Boeing, Nvidia TheStreet.com
04:06AM	Boeing, Tesla and Johnson & Johnson Fall Premarket Investing.com
03:19AM	Intellia Therapeutics Soars on Trial Results Using Crispr Technology TheStreet.com
Jun-27-21 07:25AM	Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst TipRanks
Jun-26-21 08:00PM	Crispr gene-editing revolution treats internal organ for first time Financial Times
01:07PM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
11:16AM	Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis PR Newswire
Jun-25-21 04:45AM	This Biotech Is Editing Genes Inside the Body. What It Means for the Stock. Barrons.com
Jun-24-21 07:30AM	Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary GlobeNewswire
Jun-22-21 07:00AM	Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company Business Wire
06:41AM	3 Biotech Stocks With Big Catalysts in June Motley Fool
Jun-07-21 07:11AM	What's the Best Way to Invest in Genetics Stocks? Motley Fool +7.50%
Jun-04-21 07:30AM	Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting GlobeNewswire
Jun-03-21 07:39AM	This Genetics Stock Could Have a Bright Future Motley Fool
Jun-02-21 09:40AM	10 Best Pharmaceutical Stocks to Buy According to Cathie Wood Insider Monkey
Jun-01-21 03:41AM	We're Interested To See How Intellia Therapeutics (NASDAQ:NTLA) Uses Its Cash Hoard To Grow Simply Wall St.
May-11-21 12:12PM	Cathie Woods ARK Wasnt Built for a Flood The Wall Street Journal +8.42%
May-07-21 06:00PM	Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 08:50AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates Zacks -6.84%
07:30AM	Intellia Therapeutics Announces First Quarter 2021 Financial Results GlobeNewswire
06:15AM	Intellia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-30-21 11:15AM	3 Exciting Biotech Stocks to Buy Right Now Motley Fool
Apr-29-21 05:05PM	Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out for Zacks -6.13%
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates GlobeNewswire
Apr-28-21 05:30AM	Cutting Edge Intellia Therapeutics Charts Are Bullish TheStreet.com
Apr-27-21 04:35PM	Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire
Apr-16-21 03:51PM	CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today InvestorPlace -5.78%
Apr-14-21 12:30PM	Is NTLA Stock A Buy or Sell? Insider Monkey +7.85%
Apr-12-21 07:30AM	Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors GlobeNewswire
Mar-30-21 07:30AM	Intellia Therapeutics Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis GlobeNewswire +10.61%
Mar-25-21 07:30AM	Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors GlobeNewswire
Mar-10-21 07:30AM	Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium GlobeNewswire
Mar-03-21 01:46AM	The Intellia Therapeutics (NASDAQ:NTLA) Share Price Is Up 360% And Shareholders Are Delighted Simply Wall St. -6.87%
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
Feb-26-21 12:59AM	Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4 Zacks +5.20%
Feb-25-21 09:30PM	Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript Motley Fool -9.81%
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
05:45AM	Intellia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates GlobeNewswire
Jan-29-21 09:44AM	A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains InvestorPlace
Jan-20-21 08:23AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics Zacks
Jan-15-21 06:12PM	7 CRISPR Stocks for the Future of Medicine InvestorPlace
Jan-14-21 03:11PM	With Rare Speed, Gene Editing Emerges as Biotechs New Cutting Edge Barrons.com +9.59%
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks -7.12%
Jan-08-21 09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks
Jan-07-21 04:24PM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs Investor's Business Daily +16.09%
01:05PM	Why Intellia Therapeutics Stock Is Soaring Today Motley Fool
08:42AM	3 Biotech Technological Developments to Watch Out For in 2021 Zacks
07:30AM	Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 GlobeNewswire
Jan-06-21 11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age Barrons.com +9.39%
Jan-04-21 09:27AM	5 Disruptive Biotech Stocks With Solid Long-Term Potential Zacks

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FORMELA JEAN FRANCOIS	Director	Jun 28	Sale	132.73	553,376	73,448,879	10,000	Jun 29 09:48 AM
FORMELA JEAN FRANCOIS	Director	Jun 14	Sale	87.37	170,779	14,921,294	563,376	Jun 15 09:51 AM
FORMELA JEAN FRANCOIS	Director	Jun 11	Sale	85.23	30,946	2,637,480	734,155	Jun 15 09:51 AM
FORMELA JEAN FRANCOIS	Director	Apr 29	Sale	85.43	4,513	385,546	765,101	Apr 30 08:55 PM
FORMELA JEAN FRANCOIS	Director	Apr 28	Sale	85.56	131,926	11,287,893	769,614	Apr 28 07:51 PM
FORMELA JEAN FRANCOIS	Director	Apr 27	Sale	86.22	210,230	18,125,992	901,540	Apr 28 07:51 PM
FORMELA JEAN FRANCOIS	Director	Apr 26	Sale	84.93	806	68,454	1,111,770	Apr 28 07:51 PM
LEONARD JOHN M	President and CEO	Apr 13	Option Exercise	11.16	25,937	289,506	719,305	Apr 15 08:50 PM
DORSA CAROLINE	Director	Apr 05	Option Exercise	6.40	7,500	48,000	12,910	Apr 06 06:09 PM
FORMELA JEAN FRANCOIS	Director	Apr 05	Sale	84.98	800	67,984	1,112,576	Apr 07 02:14 PM
DORSA CAROLINE	Director	Apr 05	Sale	82.19	7,500	616,405	5,410	Apr 06 06:09 PM
Rivera Jose E	EVP, General Counsel	Apr 01	Option Exercise	12.51	97,001	1,213,537	178,077	Apr 02 08:42 PM
LEONARD JOHN M	President and CEO	Apr 01	Option Exercise	14.15	71,041	1,005,049	707,263	Apr 02 08:46 PM
LEONARD JOHN M	President and CEO	Apr 01	Sale	83.64	38,209	3,195,661	681,222	Apr 02 08:46 PM
Rivera Jose E	EVP, General Counsel	Apr 01	Sale	82.46	50,455	4,160,559	131,032	Apr 02 08:42 PM
FORMELA JEAN FRANCOIS	Director	Feb 26	Sale	60.29	501,945	30,262,716	1,113,376	Mar 01 01:59 PM
LEONARD JOHN M	President and CEO	Feb 09	Option Exercise	6.83	56,718	387,384	688,579	Feb 09 08:36 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Option Exercise	18.30	21,000	384,195	129,409	Feb 09 08:38 PM
LEONARD JOHN M	President and CEO	Feb 09	Sale	75.00	28,043	2,103,225	660,536	Feb 09 08:36 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Sale	75.00	11,489	861,675	117,920	Feb 09 08:38 PM
LEONARD JOHN M	President and CEO	Feb 05	Option Exercise	13.40	40,000	536,000	654,803	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 05	Sale	67.66	22,942	1,552,185	631,861	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 03	Option Exercise	17.68	117,060	2,069,793	651,661	Feb 03 09:39 PM
LEONARD JOHN M	President and CEO	Feb 03	Sale	72.54	67,856	4,922,490	584,601	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Option Exercise	9.68	109,000	1,054,620	121,686	Feb 03 09:38 PM
LEONARD JOHN M	President and CEO	Feb 01	Option Exercise	13.69	200,000	2,737,600	598,814	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Sale	63.99	54,659	3,497,902	88,686	Feb 03 09:38 PM
LEONARD JOHN M	President and CEO	Feb 01	Sale	64.00	109,889	7,032,905	523,853	Feb 03 09:39 PM
Cohen Fred E	Director	Jan 20	Option Exercise	13.78	20,000	275,600	30,000	Jan 22 04:22 PM
Rivera Jose E	EVP, General Counsel	Jan 05	Sale	55.86	2,078	116,077	51,990	Jan 05 08:55 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Jan 05	Sale	55.86	1,377	76,919	16,656	Jan 05 08:58 PM
LEONARD JOHN M	President and CEO	Jan 05	Sale	55.86	6,239	348,511	475,488	Jan 05 09:24 PM
LEONARD JOHN M	President and CEO	Dec 31	Option Exercise	0.00	14,375	0	481,727	Jan 05 09:24 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 31	Option Exercise	0.00	4,792	0	18,033	Jan 05 08:58 PM
Rivera Jose E	EVP, General Counsel	Dec 31	Option Exercise	0.00	4,792	0	54,068	Jan 05 08:55 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 30	Option Exercise	13.48	1,500	20,220	12,673	Jan 04 09:03 PM
KARSEN PERRY A	Director	Dec 17	Option Exercise	18.45	88,764	1,637,842	93,764	Dec 18 04:29 PM
KARSEN PERRY A	Director	Dec 17	Sale	53.55	88,764	4,753,680	5,000	Dec 18 04:29 PM
Rivera Jose E	EVP, General Counsel	Dec 01	Option Exercise	13.88	5,000	69,400	52,072	Dec 03 06:42 PM
Rivera Jose E	EVP, General Counsel	Dec 01	Sale	38.21	3,364	128,525	48,708	Dec 03 06:42 PM
LEONARD JOHN M	President and CEO	Nov 27	Option Exercise	16.17	35,000	566,100	487,352	Nov 27 09:00 PM
LEONARD JOHN M	President and CEO	Nov 27	Sale	38.57	35,000	1,350,000	467,352	Nov 27 09:00 PM
LEONARD JOHN M	President and CEO	Nov 25	Option Exercise	6.83	50,000	341,500	517,352	Nov 25 08:02 PM
LEONARD JOHN M	President and CEO	Nov 25	Sale	36.00	50,000	1,800,000	467,352	Nov 25 08:02 PM
Rivera Jose E	EVP, General Counsel	Nov 18	Option Exercise	18.30	848	15,518	47,696	Nov 18 07:55 PM
Rivera Jose E	EVP, General Counsel	Nov 18	Sale	35.00	624	21,840	47,072	Nov 18 07:55 PM
Rivera Jose E	EVP, General Counsel	Nov 16	Option Exercise	7.44	10,562	78,585	52,315	Nov 18 07:55 PM
LEONARD JOHN M	President and CEO	Nov 16	Option Exercise	14.58	20,000	291,600	487,352	Nov 18 07:56 PM
LEONARD JOHN M	President and CEO	Nov 16	Sale	34.00	20,000	680,000	467,352	Nov 18 07:56 PM
Rivera Jose E	EVP, General Counsel	Nov 16	Sale	34.29	6,029	206,728	46,700	Nov 18 07:55 PM
LEONARD JOHN M	President and CEO	Nov 04	Option Exercise	6.83	50,000	341,500	517,352	Nov 06 04:38 PM
Rivera Jose E	EVP, General Counsel	Nov 04	Option Exercise	13.88	5,000	69,400	45,679	Nov 06 04:41 PM
Rivera Jose E	EVP, General Counsel	Nov 04	Sale	28.00	3,364	94,192	42,315	Nov 06 04:41 PM
LEONARD JOHN M	President and CEO	Nov 04	Sale	26.00	50,000	1,300,000	467,352	Nov 06 04:38 PM
Rivera Jose E	EVP, General Counsel	Oct 15	Option Exercise	6.83	10,000	68,300	46,294	Oct 16 08:58 PM
Rivera Jose E	EVP, General Counsel	Oct 15	Sale	24.20	5,615	135,883	40,679	Oct 16 08:58 PM
LEONARD JOHN M	President and CEO	Oct 07	Option Exercise	6.83	5,000	34,150	472,352	Oct 09 04:14 PM
LEONARD JOHN M	President and CEO	Oct 07	Sale	21.83	5,000	109,150	467,352	Oct 09 04:14 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Option Exercise	6.83	10,000	68,300	41,909	Sep 17 04:55 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Sale	21.04	5,615	118,140	36,294	Sep 17 04:55 PM
LEONARD JOHN M.	President and CEO	Sep 01	Option Exercise	6.83	5,000	34,150	472,352	Sep 03 04:15 PM
LEONARD JOHN M.	President and CEO	Sep 01	Sale	21.83	5,000	109,150	467,352	Sep 03 04:15 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Option Exercise	6.83	10,000	68,300	37,524	Aug 20 04:13 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Sale	21.00	5,615	117,915	31,909	Aug 20 04:13 PM
LEONARD JOHN M.	President and CEO	Aug 06	Option Exercise	6.83	5,000	34,150	472,352	Aug 07 07:29 PM
LEONARD JOHN M.	President and CEO	Aug 06	Sale	21.83	5,000	109,150	467,352	Aug 07 07:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience